Application of targeted therapy combined with chemotherapy in advanced gastric cancer
10.16571/j.cnki.1008-8199.2020.08.018
- VernacularTitle: 靶向治疗联合化疗在进展期胃癌中的应用进展
- Author:
Guo-xin WANG
1
;
Ping WANG
1
;
Xin-en HUANG
1
Author Information
1. Department of Medicine, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research,Jiangsu Cancer Hospital,Nanjing 210000,Jiangsu, China
- Publication Type:Journal Article
- Keywords:
gastric cancer;
chemotherapy;
targeted therapy;
Trastuzumab;
Apatinib
- From:
Journal of Medical Postgraduates
2020;33(8):873-878
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is one of the most common malignant tumors in the world. Due to its high recurrence rate, gastric cancer is the second leading cause of cancer death. Up to now, surgical treatment is the only method of cure for patients with early disease, and with the development of endoscopy, neoadjuvant radiotherapy and chemotherapy, 5-year survival rate of patients with early gastric cancer could reach more than 95%. However, no specific symptoms were reported in the early stage of gastric cancer, most patients were diagnosed with middle and late stage when they were symptomatic, and no longer candidates for surgical treatment. In recent years, treatment for gastric cancer has evolved rapidly regarding neoadjuvant chemotherapy, molecular targeted therapy and immunotherapy as well as new chemotherapeutic regimens. The representative in the first-line chemotherapy includes platinum and fluorouracil, or a combination of these two agents. Meanwhile, targeted therapy is also widely used in this setting due to its specificity. Thus, it is necessary to summarize the therapeutic effects of current targeted therapy combined with chemotherapy in treating patients with advanced gastric cancer.
